Energy Production and Metabolism Practice Questions

Q: Which complex is NADH-Coenzyme Q reductase in the electron transport chain?

Complex I. **Explanation:** The Electron Transport Chain (ETC) consists of a series of protein complexes located in the inner mitochondrial membrane that facilitate oxidative phosphorylation. **Why Complex I is correct:** **Complex I** is formally known as **NADH-Coenzyme Q reductase** (or NADH dehydrogenase). Its primary function is to accept two electrons from NADH (produced in the TCA cycle) and transfer them to **Coenzyme Q (Ubiquinone)**. During this process, it pumps four protons ($H^+$) from the mitochondrial matrix into the intermembrane space, contributing to the proton gradient. **Why other options are incorrect:** * **Complex II (Succinate-Q reductase):** This complex accepts electrons from **FADH₂** (derived from the conversion of succinate to fumarate). It does not pump protons and is not the entry point for NADH. * **Complex III (Q-cytochrome c oxidoreductase):** This complex transfers electrons from reduced Coenzyme Q (ubiquinol) to **Cytochrome c**. * **Complex IV (Cytochrome c oxidase):** This is the terminal complex that transfers electrons from Cytochrome c to **molecular oxygen**, reducing it to water ($H_2O$). **High-Yield Clinical Pearls for NEET-PG:** * **Inhibitors of Complex I:** Rotenone, Amobarbital (Amytal), and Piericidin A. * **Leber’s Hereditary Optic Neuropathy (LHON):** A mitochondrial disorder often caused by mutations in genes encoding subunits of Complex I, leading to bilateral central vision loss. * **Proton Pumping:** Complexes I, III, and IV act as proton pumps; Complex II does **not**. * **Mobile Carriers:** Coenzyme Q (lipid-soluble) and Cytochrome c (water-soluble) are the two mobile electron carriers in the ETC.

Q: The phenomenon by which cancer cells are able to sustain and proliferate under adverse conditions of hypoxia is?

Warburg effect. ### Explanation **Correct Answer: A. Warburg Effect** The **Warburg effect** refers to the unique metabolic shift in cancer cells where they prefer **aerobic glycolysis** over oxidative phosphorylation. Even in the presence of oxygen (and especially under hypoxia), cancer cells convert the majority of glucose into **lactate** rather than sending it to the mitochondria. * **Mechanism:** This rapid glucose uptake and fermentation provide the cell with carbon skeletons (intermediates) necessary for the biosynthesis of nucleic acids, proteins, and lipids required for rapid proliferation. * **Survival:** By relying on glycolysis, cancer cells can survive in the poorly vascularized, hypoxic core of a solid tumor where oxygen levels are insufficient for normal mitochondrial function. **Analysis of Incorrect Options:** * **B. Wanton effect:** This is a distractor term with no relevance to biochemistry or medical physiology. * **C. Wormian bone:** These are small, irregular accessory bones found within the sutures of the skull (e.g., seen in Osteogenesis Imperfecta or Cleidocranial Dysplasia). * **D. Wolff’s law:** A principle in orthopedics stating that bone grows or remodels in response to the physical loads/stress placed upon it. **High-Yield Clinical Pearls for NEET-PG:** 1. **PET Scan Basis:** The Warburg effect is the clinical basis for **18F-FDG PET scans**. Since cancer cells have a high rate of glycolysis, they take up the radiolabeled glucose analog (FDG) much faster than normal tissues. 2. **Key Enzyme:** Cancer cells often overexpress **Hexokinase II** and **GLUT1/3** transporters to facilitate this high glucose flux. 3. **HIF-1α:** Under hypoxia, **Hypoxia-Inducible Factor 1-alpha** is stabilized, which upregulates glycolytic enzymes and VEGF, further driving the Warburg phenotype.

Q: Which of the following is NOT an allosteric inhibitor of the TCA cycle?

ADP. The TCA cycle is the central metabolic pathway for energy production. Its regulation is governed by the **energy status** of the cell. ### **Why ADP is the Correct Answer** ADP (Adenosine Diphosphate) signifies a **low-energy state**. When ADP levels are high, the cell needs more ATP; therefore, ADP acts as an **allosteric activator**, not an inhibitor. It specifically stimulates **Isocitrate Dehydrogenase**, the rate-limiting enzyme of the TCA cycle, to increase the flow of substrates through the pathway. ### **Why the Other Options are Incorrect** These molecules signify a **high-energy state** or feedback inhibition, thus they act as inhibitors: * **ATP:** High levels signal that the cell has sufficient energy. ATP allosterically inhibits Citrate Synthase and Isocitrate Dehydrogenase. * **NADH:** A high NADH/NAD+ ratio indicates an abundance of reducing equivalents. NADH inhibits Isocitrate Dehydrogenase and α-Ketoglutarate Dehydrogenase. * **Succinyl CoA:** This is an example of **product inhibition**. It competes with Acetyl CoA at Citrate Synthase and inhibits α-Ketoglutarate Dehydrogenase. ### **High-Yield NEET-PG Pearls** * **Rate-limiting enzyme:** Isocitrate Dehydrogenase. * **Key Regulatory Steps:** 1. Citrate Synthase 2. Isocitrate Dehydrogenase 3. α-Ketoglutarate Dehydrogenase * **Calcium (Ca²⁺):** In muscle cells, Ca²⁺ acts as an important **activator** of the TCA cycle (specifically Isocitrate DH and α-Ketoglutarate DH) to link muscle contraction with energy production. * **Fluoroacetate:** A potent inhibitor of the TCA cycle that inhibits the enzyme **Aconitase**.

Q: Which complex of the electron transport chain is not associated with the liberation of energy?

Complex II. **Explanation:** The Electron Transport Chain (ETC) consists of five complexes located in the inner mitochondrial membrane. The liberation of energy in the ETC is directly coupled to the **pumping of protons ($H^+$)** from the mitochondrial matrix into the intermembrane space, creating an electrochemical gradient used for ATP synthesis. **Why Complex II is the correct answer:** Complex II (**Succinate Dehydrogenase**) is the only complex in the ETC that **does not pump protons**. It transfers electrons from Succinate to FAD, and then to Coenzyme Q. Because the redox potential change across Complex II is relatively small, it does not release enough free energy to transport protons across the membrane. Consequently, it does not contribute directly to the proton motive force required for ATP production. **Why the other options are incorrect:** * **Complex I (NADH Dehydrogenase):** Pumps **4 protons** per NADH molecule. It is the largest complex and a major site of energy liberation. * **Complex III (Cytochrome bc1 complex):** Pumps **4 protons** via the Q-cycle. * **Complex IV (Cytochrome c Oxidase):** Pumps **2 protons** into the intermembrane space while reducing oxygen to water. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Role:** Complex II is the only enzyme that participates in both the **TCA Cycle** and the **ETC**. * **Location:** Unlike other TCA enzymes which are soluble in the matrix, Complex II is **membrane-bound**. * **Inhibitors:** Complex II is inhibited by **Malonate** (competitive inhibitor) and **Carboxin**. * **P:O Ratio:** Because Complex II bypasses the proton-pumping Complex I, FADH2 oxidation yields only **1.5 ATP**, whereas NADH oxidation (starting at Complex I) yields **2.5 ATP**.

Q: An obese young woman ingested a banned drug which was once used for weight reduction and she developed high fever. The drug is known to affect the ATP formation in the electron transport chain. What could that drug be?

2,4-dinitrophenol. ### Explanation **Correct Option: C. 2,4-dinitrophenol (DNP)** The clinical presentation of weight loss followed by high fever (hyperpyrexia) after drug ingestion is a classic description of **Uncoupler** toxicity. * **Mechanism:** 2,4-DNP is a lipophilic protonophore. It picks up protons ($H^+$) from the intermembrane space and carries them across the inner mitochondrial membrane into the matrix, bypassing the $F_0F_1$ ATP synthase complex. * **Result:** This dissipates the proton gradient. While the Electron Transport Chain (ETC) continues to operate at a rapid rate (consuming oxygen), the energy is not captured as ATP. Instead, the energy is released as **heat**, leading to fatal hyperthermia. * **Historical Context:** DNP was used in the 1930s for weight loss because it "wastes" metabolic fuel, but it was banned due to its narrow therapeutic index and severe side effects. **Incorrect Options:** * **A. Barbiturates:** These are inhibitors of **Complex I** (NADH Dehydrogenase). They block the flow of electrons, thereby stopping both the ETC and ATP production, rather than uncoupling them. * **B. Malonate:** This is a classic **competitive inhibitor of Succinate Dehydrogenase** (Complex II). It competes with succinate for the active site. * **D. Rotenone:** A common insecticide that acts as an inhibitor of **Complex I**. Like barbiturates, it prevents the establishment of a proton gradient. **NEET-PG High-Yield Pearls:** * **Physiological Uncoupler:** **Thermogenin** (UCP1) found in brown adipose tissue; essential for non-shivering thermogenesis in neonates. * **Other Uncouplers:** High doses of **Aspirin (Salicylates)**, Dicumarol, and Bilirubin. * **Key Distinction:** *Inhibitors* (e.g., Cyanide, CO) stop oxygen consumption; *Uncouplers* (e.g., DNP) **increase** oxygen consumption while decreasing ATP synthesis.

Q: Which molecule typically serves as the primary source of reducing power in metabolic pathways?

NADPH. **Explanation:** The correct answer is **NADPH** (Nicotinamide Adenine Dinucleotide Phosphate). In biochemistry, it is crucial to distinguish between the roles of NADH and NADPH based on the metabolic pathways they serve. **1. Why NADPH is correct:** NADPH serves as the primary **reducing power** for **reductive biosynthesis** (anabolic pathways). While NADH is primarily used to generate ATP via the electron transport chain, NADPH provides the electrons necessary to build complex molecules. It is essential for fatty acid synthesis, cholesterol synthesis, and the regeneration of reduced glutathione to protect cells against reactive oxygen species (ROS). **2. Why the other options are incorrect:** * **NADH:** Primarily functions in **catabolic** pathways. It carries electrons from glycolysis and the TCA cycle to the mitochondria for ATP production (oxidative phosphorylation). * **FADH2:** Similar to NADH, it is an electron carrier used specifically in the electron transport chain (Complex II) to generate energy, not as a general source for biosynthesis. * **ATP:** This is the "energy currency" of the cell, providing chemical energy through phosphate bond hydrolysis, but it does not provide reducing equivalents (electrons). **3. High-Yield Clinical Pearls for NEET-PG:** * **Sources of NADPH:** The **Pentose Phosphate Pathway (PPP/HMP Shunt)** is the major source of NADPH. The rate-limiting enzyme is **Glucose-6-Phosphate Dehydrogenase (G6PD)**. * **Clinical Correlation:** In **G6PD deficiency**, the lack of NADPH leads to an inability to maintain reduced glutathione in RBCs, resulting in oxidative stress, Heinz bodies, and hemolytic anemia. * **Key Mnemonic:** **NADH** is for **D**egradation (Catabolism); **NADPH** is for **P**roduction (Anabolism/Biosynthesis).

Q: NAD+ is reduced by all of the following enzymes except:

Succinyl dehydrogenase. **Explanation:** The correct answer is **Succinyl dehydrogenase** (also known as Succinate Dehydrogenase or SDH). The underlying biochemical concept involves the specificity of electron carriers in the Citric Acid Cycle (TCA). Most dehydrogenases in the TCA cycle utilize **NAD+** as a coenzyme, which is reduced to NADH + H+. However, **Succinate Dehydrogenase** is unique because it is an integral membrane protein (Complex II of the Electron Transport Chain) that utilizes **FAD** as its prosthetic group. It oxidizes Succinate to Fumarate, reducing FAD to **FADH2**. **Analysis of Options:** * **Alpha-ketoglutarate dehydrogenase:** This multienzyme complex catalyzes the oxidative decarboxylation of $\alpha$-ketoglutarate to Succinyl-CoA, reducing **NAD+** to NADH. * **Isocitrate dehydrogenase:** This is the rate-limiting enzyme of the TCA cycle. It converts Isocitrate to $\alpha$-ketoglutarate, reducing **NAD+** to NADH. * **Malate dehydrogenase:** This enzyme catalyzes the final step of the cycle, converting Malate to Oxaloacetate while reducing **NAD+** to NADH. **High-Yield Clinical Pearls for NEET-PG:** * **Location:** Succinate Dehydrogenase is the only TCA cycle enzyme located in the **inner mitochondrial membrane**; all others are in the mitochondrial matrix. * **Inhibitor:** Malonate is a classic **competitive inhibitor** of Succinate Dehydrogenase (structurally similar to Succinate). * **Energy Yield:** Oxidation of 1 NADH yields ~2.5 ATP, whereas 1 FADH2 yields ~1.5 ATP. * **Mnemonic:** "Can I Keep Selling Substances For Money?" (Citrate, Isocitrate, $\alpha$-Ketoglutarate, Succinyl-CoA, **S**uccinate, **F**umarate, Malate). Remember: **S**uccinate to **F**umarate produces **F**ADH2.

Q: All of the following processes occur in mitochondria, except:

Fatty acid synthesis. **Explanation:** The correct answer is **Fatty acid synthesis** because it primarily occurs in the **cytosol**. This is a classic "compartmentalization" question frequently tested in NEET-PG. **1. Why Fatty Acid Synthesis is the Correct Answer:** De novo synthesis of fatty acids (Lipogenesis) occurs in the cytosol of cells, primarily in the liver, lactating mammary glands, and adipose tissue. The key enzyme, **Fatty Acid Synthase (FAS) complex**, is located in the cytoplasm. While the starting material (Acetyl-CoA) is generated in the mitochondria, it must be transported to the cytosol via the **Citrate-Malate Shuttle** because the mitochondrial membrane is impermeable to Acetyl-CoA. **2. Why the other options are incorrect:** * **TCA Cycle (Krebs Cycle):** Occurs entirely within the **mitochondrial matrix**. It is the final common pathway for the oxidation of carbohydrates, lipids, and proteins. * **Beta-oxidation of Fatty Acids:** This is the breakdown of fatty acids to generate energy, which occurs in the **mitochondrial matrix**. Fatty acids enter the mitochondria via the **Carnitine Shuttle**. * **Gluconeogenesis:** This is a **bisegmental** process. It begins in the mitochondria (Pyruvate → Oxaloacetate via Pyruvate Carboxylase) and finishes in the cytosol. Since part of it occurs in the mitochondria, it does not fit the "except" criteria. **High-Yield Clinical Pearls for NEET-PG:** * **Exclusively Mitochondrial:** TCA cycle, Beta-oxidation, Ketogenesis, Urea cycle (partial), and Heme synthesis (partial). * **Exclusively Cytosolic:** Glycolysis, HMP Shunt, Fatty acid synthesis, and Translation. * **Both (Mnemonic: "HUG"):** **H**eme synthesis, **U**rea cycle, **G**luconeogenesis. * **Key Enzyme:** The rate-limiting step of fatty acid synthesis is **Acetyl-CoA Carboxylase (ACC)**, which requires Biotin (B7).

Q: Which is the first substrate of the Krebs cycle?

Pyruvate. **Explanation:** The Krebs cycle (TCA cycle) is the final common pathway for the oxidation of carbohydrates, fats, and proteins. While **Acetyl-CoA** is the direct entry molecule that condenses with oxaloacetate, **Pyruvate** is considered the primary substrate originating from glycolysis that fuels the cycle in aerobic conditions. 1. **Why Pyruvate is correct:** In the context of carbohydrate metabolism, Pyruvate (the end product of glycolysis) is transported into the mitochondria. Here, it undergoes oxidative decarboxylation by the **Pyruvate Dehydrogenase (PDH) complex** to form Acetyl-CoA. This step is the "bridge" that links glycolysis to the Krebs cycle, making Pyruvate the initial substrate that feeds the pathway. 2. **Why other options are incorrect:** * **Acetyl-CoA:** While it is the immediate reactant that enters the cycle, it is a metabolic intermediate derived from pyruvate, fatty acids, or amino acids. * **Citrate:** This is the **first product** of the Krebs cycle, formed by the condensation of Acetyl-CoA and Oxaloacetate (catalyzed by Citrate Synthase). * **Glycine:** This is a non-essential amino acid. While it can enter metabolic pathways, it is not the primary substrate for the Krebs cycle. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** Isocitrate Dehydrogenase. * **ATP Yield:** One turn of the TCA cycle produces **10 ATP** (3 NADH = 7.5, 1 FADH₂ = 1.5, 1 GTP = 1). * **PDH Deficiency:** Leads to lactic acidosis and neurological dysfunction because the body cannot convert pyruvate to Acetyl-CoA, forcing anaerobic metabolism. * **Amphibolic Nature:** The Krebs cycle is both catabolic (energy production) and anabolic (provides precursors for heme and amino acid synthesis).

Question 1

Which complex is NADH-Coenzyme Q reductase in the electron transport chain?

Accepted Answer

Complex I

Answer

Complex II

Answer

Complex III

Answer

Complex IV

Question 2

The phenomenon by which cancer cells are able to sustain and proliferate under adverse conditions of hypoxia is?

Accepted Answer

Warburg effect

Answer

Wanton effect

Answer

Wormian bone

Answer

Wolf's law

Question 3

Which of the following is NOT an allosteric inhibitor of the TCA cycle?

Accepted Answer

ADP

Answer

ATP

Answer

NADH

Answer

Succinyl CoA

Question 4

Which complex of the electron transport chain is not associated with the liberation of energy?

Accepted Answer

Complex II

Answer

Complex I

Answer

Complex III

Answer

Complex IV

Question 5

An obese young woman ingested a banned drug which was once used for weight reduction and she developed high fever. The drug is known to affect the ATP formation in the electron transport chain. What could that drug be?

Accepted Answer

2,4-dinitrophenol

Answer

Barbiturate

Answer

Malonate

Answer

Rotenone

Question 6

Which of the following statements regarding the Electron Transport Chain (ETC) is not true?

Accepted Answer

Has no role of inorganic phosphate

Answer

Occurs in mitochondria

Answer

Generates ATP

Answer

Involves transport of reducing equivalents

Question 7

Which molecule typically serves as the primary source of reducing power in metabolic pathways?

Accepted Answer

NADPH

Answer

NADH

Answer

FADH2

Answer

ATP

Question 8

NAD+ is reduced by all of the following enzymes except:

Accepted Answer

Succinyl dehydrogenase

Answer

Alpha-ketoglutarate dehydrogenase

Answer

Isocitrate dehydrogenase

Answer

Malate dehydrogenase

Question 9

All of the following processes occur in mitochondria, except:

Accepted Answer

Fatty acid synthesis

Answer

Gluconeogenesis

Answer

TCA cycle

Answer

Beta oxidation of fatty acids

Question 10

Which is the first substrate of the Krebs cycle?

Accepted Answer

Pyruvate

Answer

Glycine

Answer

Acetyl-CoA

Answer

Citrate

Energy Production and Metabolism — MCQs

Energy Production and Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?